Do analysts rate VECT or IFRX?

InflaRx has a consensus target price of $7.00, suggesting a potential upside of 283.56%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than VectivBio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VectivBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InflaRx 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Which has stronger earnings & valuation, VECT or IFRX?

VectivBio has higher earnings, but lower revenue than InflaRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VectivBio N/A N/A N/A N/A N/A InflaRx $30K 4,397.64 -$51.63M -$0.71 N/A

Is VECT or IFRX more profitable?

VectivBio's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets VectivBio N/A N/A N/A InflaRx N/A -88.30% -65.77%

Is EIKN or IFRX more profitable?

Eikon Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A InflaRx N/A -88.30% -65.77%

Does the media refer more to EIKN or IFRX?

In the previous week, Eikon Therapeutics had 2 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Eikon Therapeutics and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.00 beat Eikon Therapeutics' score of -0.45 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IFRX or CTNM more profitable?

Contineum Therapeutics' return on equity of -27.09% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Contineum Therapeutics N/A -27.09% -25.64%

Which has stronger earnings and valuation, IFRX or ARVN?

InflaRx has higher earnings, but lower revenue than Arvinas. InflaRx is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InflaRx $30K 4,397.64 -$51.63M -$0.71 N/A Arvinas $262.60M 1.99 -$80.80M -$3.32 N/A

Is IFRX or ARVN more profitable?

InflaRx has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -88.30% -65.77% Arvinas -247.54% -44.38% -28.38%

Does the media refer more to IFRX or ARVN?

In the previous week, Arvinas had 1 more articles in the media than InflaRx. MarketBeat recorded 2 mentions for Arvinas and 1 mentions for InflaRx. Arvinas' average media sentiment score of 0.98 beat InflaRx's score of 0.00 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arvinas 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PROK or IFRX more profitable?

InflaRx has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets ProKidney -8,131.50% N/A -21.39% InflaRx N/A -88.30% -65.77%

InflaRx (IFRX) Competitors

$1.82 +0.01 (+0.27%)

As of 01:42 PM Eastern

Compare

IFRX vs. VECT, EIKN, CTNM, ARVN, and PROK

Should you buy InflaRx stock or one of its competitors? MarketBeat compares InflaRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InflaRx include VectivBio (VECT), Eikon Therapeutics (EIKN), Contineum Therapeutics (CTNM), Arvinas (ARVN), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry.

How does InflaRx compare to VectivBio?

VectivBio (NASDAQ:VECT) and InflaRx (NASDAQ:IFRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

42.4% of InflaRx shares are owned by institutional investors. 9.7% of VectivBio shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, InflaRx had 1 more articles in the media than VectivBio. MarketBeat recorded 1 mentions for InflaRx and 0 mentions for VectivBio. VectivBio's average media sentiment score of 0.00 equaled InflaRx'saverage media sentiment score.

Company	Overall Sentiment
VectivBio	Neutral
InflaRx	Neutral

InflaRx has a consensus target price of $7.00, suggesting a potential upside of 283.56%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than VectivBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VectivBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

VectivBio's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VectivBio	N/A	N/A	N/A
InflaRx	N/A	-88.30%	-65.77%

VectivBio has higher earnings, but lower revenue than InflaRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VectivBio	N/A	N/A	N/A	N/A	N/A
InflaRx	$30K	4,397.64	-$51.63M	-$0.71	N/A

Summary

InflaRx beats VectivBio on 8 of the 10 factors compared between the two stocks.

How does InflaRx compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and InflaRx (NASDAQ:IFRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

In the previous week, Eikon Therapeutics had 2 more articles in the media than InflaRx. MarketBeat recorded 3 mentions for Eikon Therapeutics and 1 mentions for InflaRx. InflaRx's average media sentiment score of 0.00 beat Eikon Therapeutics' score of -0.45 indicating that InflaRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.4% of InflaRx shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eikon Therapeutics has higher earnings, but lower revenue than InflaRx. Eikon Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	N/A	-$2.46	N/A
InflaRx	$30K	4,397.64	-$51.63M	-$0.71	N/A

Eikon Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
InflaRx	N/A	-88.30%	-65.77%

Eikon Therapeutics currently has a consensus price target of $25.20, suggesting a potential upside of 156.62%. InflaRx has a consensus price target of $7.00, suggesting a potential upside of 283.56%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

InflaRx beats Eikon Therapeutics on 9 of the 13 factors compared between the two stocks.

How does InflaRx compare to Contineum Therapeutics?

InflaRx (NASDAQ:IFRX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

InflaRx currently has a consensus price target of $7.00, indicating a potential upside of 283.56%. Contineum Therapeutics has a consensus price target of $20.00, indicating a potential upside of 44.56%. Given InflaRx's stronger consensus rating and higher probable upside, equities analysts plainly believe InflaRx is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Contineum Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

InflaRx has higher revenue and earnings than Contineum Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,397.64	-$51.63M	-$0.71	N/A
Contineum Therapeutics	N/A	N/A	-$59.98M	-$1.95	N/A

Contineum Therapeutics' return on equity of -27.09% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Contineum Therapeutics	N/A	-27.09%	-25.64%

42.4% of InflaRx shares are held by institutional investors. 16.3% of InflaRx shares are held by company insiders. Comparatively, 7.9% of Contineum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, InflaRx had 1 more articles in the media than Contineum Therapeutics. MarketBeat recorded 1 mentions for InflaRx and 0 mentions for Contineum Therapeutics. InflaRx's average media sentiment score of 0.00 equaled Contineum Therapeutics'average media sentiment score.

Company	Overall Sentiment
InflaRx	Neutral
Contineum Therapeutics	Neutral

InflaRx has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Contineum Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Summary

InflaRx beats Contineum Therapeutics on 12 of the 14 factors compared between the two stocks.

How does InflaRx compare to Arvinas?

InflaRx (NASDAQ:IFRX) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

In the previous week, Arvinas had 1 more articles in the media than InflaRx. MarketBeat recorded 2 mentions for Arvinas and 1 mentions for InflaRx. Arvinas' average media sentiment score of 0.98 beat InflaRx's score of 0.00 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arvinas	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InflaRx currently has a consensus target price of $7.00, indicating a potential upside of 283.56%. Arvinas has a consensus target price of $15.42, indicating a potential upside of 90.33%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

InflaRx has higher earnings, but lower revenue than Arvinas. InflaRx is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	4,397.64	-$51.63M	-$0.71	N/A
Arvinas	$262.60M	1.99	-$80.80M	-$3.32	N/A

InflaRx has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-88.30%	-65.77%
Arvinas	-247.54%	-44.38%	-28.38%

InflaRx has a beta of 2.44, indicating that its share price is 144% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 7.3% of Arvinas shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

InflaRx beats Arvinas on 9 of the 17 factors compared between the two stocks.

How does InflaRx compare to ProKidney?

ProKidney (NASDAQ:PROK) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

51.6% of ProKidney shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 39.8% of ProKidney shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InflaRx has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. ProKidney's return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProKidney	-8,131.50%	N/A	-21.39%
InflaRx	N/A	-88.30%	-65.77%

ProKidney currently has a consensus price target of $12.00, suggesting a potential upside of 652.35%. InflaRx has a consensus price target of $7.00, suggesting a potential upside of 283.56%. Given ProKidney's higher possible upside, research analysts clearly believe ProKidney is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, InflaRx had 1 more articles in the media than ProKidney. MarketBeat recorded 1 mentions for InflaRx and 0 mentions for ProKidney. ProKidney's average media sentiment score of 0.30 beat InflaRx's score of 0.00 indicating that ProKidney is being referred to more favorably in the media.

Company	Overall Sentiment
ProKidney	Neutral
InflaRx	Neutral

ProKidney has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market.

InflaRx has lower revenue, but higher earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	$890K	541.33	-$68.99M	-$0.53	N/A
InflaRx	$30K	4,397.64	-$51.63M	-$0.71	N/A

Summary

ProKidney and InflaRx tied by winning 8 of the 16 factors compared between the two stocks.

Get InflaRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IFRX vs. The Competition

Export

Metric	InflaRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$131.93M	$3.65B	$6.80B	$12.43B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-2.57	20.62	27.03	24.19
Price / Sales	4,397.64	311.45	515.69	92.93
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.81	8.13	10.67	6.24
Net Income	-$51.63M	$23.81M	$3.59B	$331.42M
7 Day Performance	-9.20%	-1.31%	-0.60%	-1.18%
1 Month Performance	1.11%	2.40%	1.63%	-1.34%
1 Year Performance	112.95%	44.89%	25.09%	18.73%

InflaRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IFRX InflaRx	2.1072 of 5 stars	$1.83 +0.3%	$7.00 +283.6%	+110.6%	$131.93M	$30K	N/A	60
VECT VectivBio	N/A	$16.85 flat	N/A	N/A	$573.24M	$27.34M	N/A	30	High Trading Volume
EIKN Eikon Therapeutics	1.8583 of 5 stars	$10.58 -5.7%	$25.20 +138.2%	N/A	$572.79M	N/A	N/A	384	News Coverage
CTNM Contineum Therapeutics	1.627 of 5 stars	$15.19 -1.7%	$20.00 +31.7%	+211.0%	$567.95M	$50M	N/A	31
ARVN Arvinas	3.1802 of 5 stars	$8.27 -3.2%	$15.42 +86.4%	+9.1%	$533.58M	$262.60M	N/A	420	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IFRX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InflaRx (IFRX) Competitors